glp-1 receptor agonist pancreatitis risk meta-analysis Cardiovascular Effects and Tolerability of Agonists: A Systematic Review and of 99,599 Patients Dose-dependent pancreatitis risk associated with

Therapy in the early stage: incretins

Efficacy and safety of glucagonlike peptide1 receptor agonists in type 2 diabetes: a systematic review and mixedtreatment comparison analysis

However, the benefits of tirzepatide are not limited only to weight loss and glycaemic control

326 , F545f559 (2024)

Whether it's being degraded in the gastric acid, or prematurely being activated in the stomach and not absorbed in the small intestine due to delayed gastric emptying from GLP-1 therapies

Preliminary safety analyses indicate that tirzepatide does not cause severe hypoglycemia and shows no adverse effects on central respiratory control (59)